HealthCare Journey for Multiple Sclerosis
  • Home
  • About Us
  • Virtual MS Center
    • Q & A for Virtual MS Center
    • Read About Our Virtual MS Center Staff
  • News & Resources
  • Seminar Registration
  • Health & Wellness
  • Blogs
    • Physician Blog >
      • Healthcare Provider Blog
    • Physical Therapy Blog
    • Patient Blog
    • Caregiver Blog
    • Research Blogs >
      • "Ask Dr. Debbie" Research Blog
      • Multiple Perspectives In Multiple Sclerosis Research Blog
  • About MS
    • What is MS?
    • Diagnosis
    • Treatment
    • MS Tips
  • Symptoms
    • Balance and Walking Issues
    • Breathing/Respiratory
    • Bowel Dysfunction
    • Cognitive Dysfunction
    • Crying/Laughing Uncontrollably (PBA)
    • Depression and Anxiety
    • Dizziness/Vertigo
    • Dysphagia
    • Fatigue
    • Foot Drop
    • Hearing or Smell or Taste Changes
    • Heat Sensitivity
    • Leg Weakness
    • Loss of Hand Dexterity and Coordination
    • Memory and Mutliple Sclerosis
    • Migraines
    • Numbness/Tingling/Altered Sensation
    • Nystagmus and Oscillopsia
    • Pain
    • Sexual Dysfunction
    • Sleep Issues
    • Spasticity/Spasms/Cramps
    • Speech/Swallowing
    • Urination/Bowel Problems
    • Vision
  • MS Clinics
  • MS Topics
    • Pregnancy and Infertility
    • Caregivers and Family Members
    • Employment and MS
    • Medical Costs and Insurance
    • Pediatric Multiple Sclerosis
  • Register With Us
  • Terms of Use/Privacy/HIPAA
  • MS HealthCare Journey

Welcome to the Virtual MS Center!

Ask any question you want about Multiple Sclerosis and one of our experts will answer it as soon as possible.
CLICK HERE TO ASK YOUR QUESTION!

JCV granule cell neuronopathy

3/17/2015

 
Question:
My daughter has had MS for 20 years. She has been on Tysabri for almost 5 years. She was diagnosed with JVC granular cell neuropathy of the cerebellum in September 2014. Her spinal copies were 267. As of feb 2015 they were at 58. Could someone please explain to us in plain English how do we know when this infection is gone? My daughter is tired all the time. How hard should she push herself to do everyday things? Her symptoms are numerous and she doesn't seem to be improving. Does the cerebellum once compromised repair itself? Are their symptoms that indicate we need to be even more worried that something is really wrong or that we could be facing death if not treated? Right now my daughter is on no maintance drugs for her MS. I am really concerned about this but should I be? Lastly is there any layman phamplets or literature you could direct me to. We do have an excellent MS doctor but he is not an expert on this mutant gene of JVC and therefore consults with other doctors. My daughter is on her 7th month of this virus and we are all concerned. Thank you.

Answer:
We are very sorry to hear about your daughter's diagnosis. You seem very knowledgeable about her particular condition but let us provide some general information that may benefit other readers and answer your specific question.

The John Cunningham Virus (JCV) is ubiquitous (meaning it exists everywhere in the world), only infects humans and does not appear to cause any primary illness when a person gets infected. The number of people infected with this virus varies from study to study, but most studies suggest that more than 80 % of all people are infected with this virus. Following infection the JCV remains asymptomatic in the bone marrow and kidneys (whether or not you have MS).  Some people produce detectable antibodies after infection with the JC virus infection, whereas others do not. The present or absence of antibodies to the JC virus using the current assay available for MS patients, does not indicate whether you have a latent or prior infection with the JC virus, but it does indicate your risk of developing a productive JCV infection of the nervous system, if you are receiving treatment with Tysabri.

Due to reasons that are not entirely clear, people who are immunosuppressed and people who are receiving certain treatments, particularly natalizumab, may experience a productive infection of the central nervous system by the JC virus. For this to occur, one or more genes expressed by the virus must become mutated to cause the infection in the brain. What causes the mutations, allows the virus to be transported to the nervous system so that an infection may develop, and allows the virus to enter brain cells not normally infected by the original virus (called the archetypal strain) and reproduce remains unclear at this time.

The most common central nervous system infection by a mutated JC Virus is called Progressive Multifocal Leukoencephalopathy (PML). This is an infection of the oligodendrocytes that make myelin in the brain. It is this same myelin that is the target of inflammation in MS. Therefore, the initial symptoms of PML can be confused with worsening of MS and the diagnosis of PML requires a high degree of vigilance. Less commonly, the mutated virus can infect the granule cell neurons in the cerebellum and cause a condition called JCV granule cell neuronopathy. This condition does not directly affect oligodendrocytes or myelin and  can be very difficult to detect since patients experience a progressive shrinkage of the cerebellar cortex without the white matter changes typically associated with PML on MRI scans. MRI is very good at detecting changes in the white matter of the brain (such as MS and PML) but not as good at detecting changes in the cortex or gray matter (such JCV granule cell neuronopathy). In some cases people present with both typical PML and Granule cell neuropathy of the cerebellum making it easier to establish a diagnosis. The symptoms of JCV granule cell neuronopathy usually include progressive unsteadiness walking (called ataxia or walking like a drunk), slurred slow speech with loss of normal rhythm (called dysarthria) and incoordination of movements. While these same symptoms can be caused by MS, their development or worsening in an otherwise stable MS patient on long term Tysabri therapy is reason to suspect JCV granule cell neuronopathy.

To date, there have been over 130,000 individuals throughout the world that have been exposed to Tysabri. The overwhelming majority of patients with JCV related nervous system infections are reported as PML although it is likely that other JCV related conditions like JCV granule cell neuronopathy may go undetected or misdiagnosed. 

Once a Tysabri treated patient develops PML, there is a 23% mortality rate, and the other 77% of patients survive the infection but are left with varying levels of disability.  In some cases the virus is eliminated and no longer detected after the immune response is restored (read below). In other cases like your daughter, the virus remains detectable in low amounts for variable periods of time because of partial viral clearance by the immune system response.  In this case the condition becomes chronic much like the underlying multiple sclerosis. Physical/Occupational therapy may be indicated to help facilitate some functional recovery.  Your doctors can help direct this when it is most appropriate. We know far less about the outcomes of people with MS who develop JCV granule cell neuritis as there are very few reported cases.

When PML occurs on Tysabri treatment, the generally accepted strategy to manage this situation is to remove the Tysabri from the patient by using plasma exchange (this is a procedure that filters the blood, removing the Tysabri).  This is done in a hospital setting.  The rationale for this is to remove the blockade of white blood cells from the nervous system (so they can get into this space and fight off the infection).  Following plasma exchange the patient often develops a strong inflammatory response against the infected brain that worsens their condition and is usually controlled with steroid treatment. This is call an Immune Response Inflammatory Syndrome or IRIS. Unfortunately, there is no proven additional therapy that can eradicate the virus.  Therefore, we rely on the strength of the immune system to clear the virus.  Periodic testing of the spinal fluid is important to prove that the immune system has successfully cleared the virus. 

To answer your question about a disease modifying therapy to treat your daughter's MS:  we would agree with your daughter's treating physician not to treat at this point in time as she still has copies of the virus in her spinal fluid. From your message, we suspect that the MS doctor appropriately has an infectious disease specialist helping in the medical care of your daughter and her PML. The world’s expert on your daughter’s condition (JCV granule cell neuronopathy) is a former colleague at Beth Israel Deaconess Medical Center in Boston, Dr Igor Koralnik. I would suggest that your daughter's doctor contact Igor for advice on management, if they have not already done so.

Revere Kinkel MD and A. Scott Nielsen MD MMSc
Brendan W. Bauer M.D.
11/4/2015 04:17:53 pm

That explanation was very thorough and spot on as I had a patient who developed the granule cell neuronopathy with the tysabri expose and she was stopped just shy of 100 treatmernts. What I found very interesting is that her IRIS rebounding of her immune system was quite prolonged as I used IVIG at the 3 month mark but this truly came at the 6-7 month mark and I wonder if having patients on Tysabri for as long as this patient was is there a prolonged or delayed IRIS response. The fatigue in my patient was gone after year 2 with Tyusabri and I truly believe that the fatigue coming back and I mean severe fatigue may be a good mnarker of the beginning of IRIS as it is antibodies that make us all tired when we mount an immune response even in the common cold. I treated my patient with Mefloquine which was shown to be negative in PML treatment but as we know this is JCV but not PML. I added a medication to bind the 5HT receptors and this was proposed that the virus uses this receptor to tranfect the cells. I added this to see if I counld keep the virus out side of the cell as much as possible and I did this because Mefloquine had toxic effects to JCV in-vitro and not invivo and I feel that the blocking of JCV uptake is crucial to its eradication. Also if your daughter did not go on a disease modifying therapy I used IVIG to help contain the MS from relapses but also not criple the immune system any further., I was unable to get my patients counts down and I did perform serial spinal studies to assess for JCV DNA titers and I used the NIH for this but Igor Koralknik was extremely helpful and could also do the DNA measure as well as to check for JCV mutations., I was able to get my patients counts of JCV down to 0 on 3 separate spinal studies done 2 months apart each. I also minimized damage to the cerebellum and I also had no progression of the MS on MRI done every 6 months., I am using IVIG every 3 months to again keep the MS stable and again when the fatigue comes back I know that the MS is knocking at the door and the IVIG every 3 months is my answer to what to use that wont supress the immune system but will keep the MS at bay until I commit to another DMT. I hope this helps and you are free to contact me with any questions as Dr Kinkle was very helpful in providing me some guidance on other options,. I also sent the CSF to 3 different labs including Boston, Mayo clinic and NIH,

Jean Noreen
12/6/2016 09:04:58 pm

My son who is now 36 also had JCVGCN. He was on Tysabri for 63 months He was diagnosed in May 2013 and also eventually had his blood work done by Dr. Koralnik, He was initially treated in May with plasma exchange for 5 days (PLEX) then 5 days of IV methylprednisolone. to prevent IRIS. Also he started on 15 mg. of mirtazapine which graduated up to 45 mg over the next few months. 4 weeks later his symptoms were much worse and he was treated with 7 days of IV methylprednisoone and started on Maraviroc, while remaining on an increased dose of mirtazapine. CSF JC viral load was 16,489 copies/ml. By October his JCV CSF PCR was negative. He started on copaxone as soon as his viral load was 0. He stayed on that for over a year, then tried Tecfidera until it was known there is a PML risk, then switched back to copaxone 40mg with LDN. 3 years later he still has cerebellar ataxia, and dysarthria. He continures with therapy and looking for anything that will help with cerebellar recovery.
Note:If the writer of the original question on 3/17/15 would like to contact me, you can give them my email address.


Comments are closed.

    RSS Feed

    PLEASE NOTE: This information/opinions on this site should be used as an information source only.  This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment.  Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.
    Read About Our Virtual MS Center Authors

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    July 2013
    June 2013

    Categories

    All
    Accessible Housing And Environmental Modifications
    Anxiety
    Balance
    Bowel Problems
    Caregivers
    Cognitive Function
    Compliance
    David Rintell Ed. D.
    Deborah Backus Blogs
    Depression
    Diagnosis
    Diet
    Dizziness
    Dosing
    Dr. Greenberg's Q&A
    Dr. Kinkel's Q&A
    Dr. Miravalle's Q&A
    Dr. Nielsen's Q&A
    Dr. Osborne's Q&A
    Exercise
    Experimental Treatments
    Eye Surgery
    Fatigue
    Fatique
    Flu Shot
    Foot Drop
    Herbs
    Immunosuppression
    JCV
    Lasik Surgery
    Lesions
    Lori Kostich's Q&A
    Lyme Disease
    Medications
    Migraines
    Mobility
    MRI
    MS Hug
    Other Diseases
    Pain
    PML
    PPMS
    Pregnancy
    Relapse
    Safety
    Sarah Wargo's Q&A
    Sexual Dysfunction
    Side Effects
    Smoking
    Spasticity
    Stem Cell Transplantation
    Steroids
    Stress
    Supplements
    Surgery
    Symptoms
    Treatment
    Urination
    Viruses
    Vision
    Vitamin D
    Vitamins
    Weakness


© 2022 HealthCare Journey, LLC. All Rights Reserved.
HealthCare Journey™ is a trademark of HealthCare Journey, LLC
Picture
  • Home
  • About Us
  • Virtual MS Center
    • Q & A for Virtual MS Center
    • Read About Our Virtual MS Center Staff
  • News & Resources
  • Seminar Registration
  • Health & Wellness
  • Blogs
    • Physician Blog >
      • Healthcare Provider Blog
    • Physical Therapy Blog
    • Patient Blog
    • Caregiver Blog
    • Research Blogs >
      • "Ask Dr. Debbie" Research Blog
      • Multiple Perspectives In Multiple Sclerosis Research Blog
  • About MS
    • What is MS?
    • Diagnosis
    • Treatment
    • MS Tips
  • Symptoms
    • Balance and Walking Issues
    • Breathing/Respiratory
    • Bowel Dysfunction
    • Cognitive Dysfunction
    • Crying/Laughing Uncontrollably (PBA)
    • Depression and Anxiety
    • Dizziness/Vertigo
    • Dysphagia
    • Fatigue
    • Foot Drop
    • Hearing or Smell or Taste Changes
    • Heat Sensitivity
    • Leg Weakness
    • Loss of Hand Dexterity and Coordination
    • Memory and Mutliple Sclerosis
    • Migraines
    • Numbness/Tingling/Altered Sensation
    • Nystagmus and Oscillopsia
    • Pain
    • Sexual Dysfunction
    • Sleep Issues
    • Spasticity/Spasms/Cramps
    • Speech/Swallowing
    • Urination/Bowel Problems
    • Vision
  • MS Clinics
  • MS Topics
    • Pregnancy and Infertility
    • Caregivers and Family Members
    • Employment and MS
    • Medical Costs and Insurance
    • Pediatric Multiple Sclerosis
  • Register With Us
  • Terms of Use/Privacy/HIPAA
  • MS HealthCare Journey